GCTK Share Price Performance
US$6.02
-1554.10 (-99.61%)
Price US$6.02
Share PriceUS$6.02
GCTK Community Narratives
There are no narratives available yet.
Recent GCTK News & Updates
No updates
GlucoTrack, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -46.70
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 2.9%
GlucoTrack, Inc. Competitors
About GCTK
- Founded
- 2001
- Employees
- 11
- CEO
- WebsiteView website
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading